Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of guselkumab in pediatric patients with moderately to severely active ulcerative colitis
CTR20234114Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Feb 2024; status: active.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20234114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234114.